Literature DB >> 30746564

Association between physical activity and dementia's risk factors in patients with Parkinson's disease.

Mohammad Alwardat1, Tommaso Schirinzi2, Giulia Di Lazzaro1, Giulia Maria Sancesario3, Donatella Franco1, Paola Imbriani1,4, Paola Sinibaldi Salimei5, Sergio Bernardini3, Nicola Biagio Mercuri1,4, Antonio Pisani1,4.   

Abstract

Evidence suggests that physical activity (PA) exerts beneficial effects on neurodegenerative processes, either as symptomatic relief or disease-modifying strategy. Actually, it may represent a viable neuroprotective intervention in Parkinson's disease dementia (PDD), a severe, frequent, and untreatable complication of Parkinson's disease (PD). According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content. Amount of PA was measured by the International Physical Activity Questionnaires-Short Form (IPAQ-SF) in 128 cognitively intact PD patients and correlated with the Hamilton-Depression (HAM-D) and the Hamilton-Anxiety (HAM-A) scores; in a homogenous subgroup of 40 patients, it was further correlated with a panel of CSF biomarkers, including amyloid-β42, total α-synuclein, total, and phosphorylated tau. The statistical model was corrected for the main potential confounding factors (motor impairment, dopaminergic treatment, disease duration, age, and sex). Both the HAM-A and HAM-D scores, as well as the Aβ42 CSF content, improved in parallel with the increase of the total week amount of PA. Although with several limitations, we preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration. However, confirmative studies are necessary to validate the efficacy of PA as protective intervention for PDD.

Entities:  

Keywords:  CSF biomarkers; Frailty; Neuroprotection; Parkinson’s disease; Parkinson’s disease dementia; Physical activity

Mesh:

Substances:

Year:  2019        PMID: 30746564     DOI: 10.1007/s00702-019-01979-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

Review 1.  Parkinson's disease.

Authors:  Lorraine V Kalia; Anthony E Lang
Journal:  Lancet       Date:  2015-04-19       Impact factor: 79.321

Review 2.  The Glymphatic System: A Beginner's Guide.

Authors:  Nadia Aalling Jessen; Anne Sofie Finmann Munk; Iben Lundgaard; Maiken Nedergaard
Journal:  Neurochem Res       Date:  2015-05-07       Impact factor: 3.996

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

4.  Serotonin, β-amyloid, and cognition in Parkinson disease.

Authors:  Vikas Kotagal; Cathie Spino; Nicolaas I Bohnen; Robert Koeppe; Roger L Albin
Journal:  Ann Neurol       Date:  2018-05-11       Impact factor: 10.422

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease.

Authors:  Adrienne Dorr; Bhupinder Sahota; Lakshminarayan V Chinta; Mary E Brown; Aaron Y Lai; Keran Ma; Cheryl A Hawkes; JoAnne McLaurin; Bojana Stefanovic
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

Review 7.  Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases.

Authors:  Carlo Alberto Artusi; Murli Mishra; Patricia Latimer; Joaquin A Vizcarra; Leonardo Lopiano; Walter Maetzler; Aristide Merola; Alberto J Espay
Journal:  Parkinsonism Relat Disord       Date:  2017-07-26       Impact factor: 4.891

8.  A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Cristiano Ialongo; Paola Imbriani; Graziella Madeo; Sofia Toniolo; Alessandro Martorana; Antonio Pisani
Journal:  Front Neurol       Date:  2015-04-23       Impact factor: 4.003

9.  Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease.

Authors:  Nadeeka N W Dissanayaka; Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; David P Breen; Tien K Khoo; Roger A Barker; David J Burn
Journal:  Parkinsonism Relat Disord       Date:  2017-01-04       Impact factor: 4.891

Review 10.  Serotonin in Parkinson's disease.

Authors:  Marios Politis; Flavia Niccolini
Journal:  Behav Brain Res       Date:  2014-07-31       Impact factor: 3.332

View more
  4 in total

Review 1.  Is transcranial direct current stimulation (tDCS) effective for chronic low back pain? A systematic review and meta-analysis.

Authors:  Mohammad Alwardat; Antonio Pisani; Mohammad Etoom; Roberta Carpenedo; Elisabetta Chinè; Mario Dauri; Francesca Leonardis; Silvia Natoli
Journal:  J Neural Transm (Vienna)       Date:  2020-07-09       Impact factor: 3.575

Review 2.  COVID-19: dealing with a potential risk factor for chronic neurological disorders.

Authors:  Tommaso Schirinzi; Doriana Landi; Claudio Liguori
Journal:  J Neurol       Date:  2020-08-27       Impact factor: 4.849

Review 3.  What and How Can Physical Activity Prevention Function on Parkinson's Disease?

Authors:  Baozhu Fan; Riffat Jabeen; Bing Bo; Chunlei Guo; Mengjie Han; Hui Zhang; Juan Cen; Xinying Ji; Jianshe Wei
Journal:  Oxid Med Cell Longev       Date:  2020-02-13       Impact factor: 6.543

4.  Effects of head trauma and sport participation in young-onset Parkinson's disease.

Authors:  Tommaso Schirinzi; Piergiorgio Grillo; Giulia Di Lazzaro; Henri Zenuni; Chiara Salimei; Kristen Dams-O'Connor; Giulia Maria Sancesario; Nicola Biagio Mercuri; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2021-07-14       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.